Treatment for erectile dysfunction is selected according to its causes, medical safety and personal priorities. This guide explains the main UK options.
Erectile dysfunction can usually be treated. Oral PDE5 inhibitors such as sildenafil or tadalafil are a common first option, but treatment should also address underlying health, medicines and psychological factors. Vacuum devices, locally acting medicines, injections and penile implants provide alternatives when tablets are unsuitable or ineffective.
| Treatment | When it may be considered | Main limitations or cautions |
|---|---|---|
| Lifestyle and risk-factor management | Recommended alongside ED treatment, especially with smoking, inactivity or cardiovascular and metabolic risk | Benefits vary and may take time; it does not replace treatment of established disease |
| Psychosexual therapy or CBT | Anxiety, depression, relationship factors or distress are contributing | Access and waiting times vary; physical contributors may also need treatment |
| PDE5 inhibitor tablet | First-line medicine for many men with ED | Needs sexual stimulation; cannot be used with nitrates or nitrite “poppers”; other contraindications and interactions apply |
| Vacuum erection device | A drug-free option or when tablets are unsuitable or ineffective | Can cause bruising, numbness or restricted ejaculation; correct ring use is essential |
| Topical or intraurethral alprostadil | Oral medicines are unsuitable, not wanted or unsuccessful | May cause penile burning or pain and is generally less effective than injection treatment |
| Penile injection treatment | A potent option for men who do not respond to tablets or choose it after counselling | Requires training; pain, fibrosis, bleeding and priapism are possible |
| Low-intensity shockwave therapy | Selected, well-informed men with mild vasculogenic ED or a poor PDE5 response | Average improvement is modest, protocols vary and long-term benefit is uncertain |
| Penile implant | Other treatments fail, cannot be used or a man prefers a surgical solution after full counselling | Requires surgery and carries infection, device-failure and revision risks |
ED is a symptom. Treatment may therefore include management of a separate condition as well as support for erections.
Blood pressure, diabetes, abnormal lipids, smoking, physical inactivity and excess weight can impair vascular function. Appropriate treatment reduces wider health risk and may improve erectile function in some men. Cardiovascular assessment also determines whether sexual activity and a vasodilating ED medicine are safe.
Some antidepressants, blood-pressure medicines, anti-androgen treatments and other drugs can contribute to sexual dysfunction. A prescriber can consider timing, dose and suitable alternatives. Do not stop or reduce prescribed treatment without medical advice.
Testosterone treatment may help sexual symptoms when a man has compatible symptoms and repeatedly low, appropriately measured testosterone. It is not a general erection treatment and should not be prescribed solely because ED is present. Men with normal testosterone are unlikely to gain erectile benefit and may be exposed to unnecessary risks.
Peyronie’s disease, pelvic trauma, spinal or neurological disease, and the effects of pelvic surgery or radiotherapy may require specialist management. The best erection treatment can differ according to the degree of nerve, arterial or tissue damage.
The EAU recommends lifestyle change and risk-factor modification before or at the same time as ED treatment. Relevant measures include:
These measures support general health and may improve erections, particularly in vasculogenic ED. They should be discussed without stigma and without promising that lifestyle change will reverse established nerve or vascular damage.
Therapy may help when performance anxiety, low mood, relationship difficulties, sexual trauma or unhelpful patterns of attention are involved. It can also help a man adjust to physically caused ED and reduce pressure around treatment.
Approaches include psychosexual education, cognitive behavioural therapy (CBT), sexual-skills work and couples therapy. The EAU recommends CBT when indicated and notes that combining psychological and medical treatment can improve outcomes. A partner can be involved with the patient’s agreement, but partner participation is not a requirement for treatment.
Sildenafil, tadalafil, vardenafil and avanafil inhibit phosphodiesterase type 5 (PDE5), helping the natural nitric-oxide pathway maintain increased blood flow in the penis. They require sexual stimulation and do not directly increase libido, ejaculation or fertility.
The choice depends on desired duration, timing, food effects, side effects, other medicines and personal preference. Sildenafil and vardenafil are relatively short acting. Tadalafil has a longer response window and can also be prescribed in a low daily dose for suitable men. Avanafil has a relatively rapid labelled dosing time.
All PDE5 inhibitors are contraindicated with:
Nicorandil must also not be combined with a PDE5 inhibitor. Treatment may be unsafe with unstable cardiovascular disease, very low blood pressure, a recent heart attack or stroke, particular eye conditions, or severe liver or kidney disease. Product-specific restrictions differ. Alpha-blockers, several antifungals, antibiotics and HIV medicines can interact or require dose adjustment. A prescriber or pharmacist must review the complete medication list.
Follow the directions for the exact product and dose supplied. Common reasons for an apparent failure include:
Do not increase the dose, take more than the maximum frequency, combine two PDE5 inhibitors or add another ED treatment without clinical advice. If one option is ineffective despite correct use, review the diagnosis, safety and technique before switching or escalating treatment.
A vacuum erection device places a cylinder over the penis and uses negative pressure to draw blood into it. A constriction ring at the base helps maintain the erection after the cylinder is removed. It is a drug-free option and can work across several causes of ED.
Possible disadvantages include a cool or numb sensation, bruising, discomfort and restricted ejaculation. The EAU advises removing the constriction ring within 30 minutes to avoid tissue injury. Men with a bleeding disorder or taking anticoagulants need individual advice because bruising or bleeding risk may make a device unsuitable.
Use a medical-grade device with clear instructions. Improvised constriction devices can cause injury.
Alprostadil is a prostaglandin that increases local blood flow. Depending on availability and suitability, it may be supplied as a cream applied at the urethral opening or a small intraurethral pellet. It can provide an alternative when oral treatment cannot be used.
Penile or urethral burning, redness and pain are common limitations. Dizziness or low blood pressure can occur, and priapism is uncommon but important. The prescriber should explain application, partner precautions and what to do if an erection persists.
Intracavernosal treatment delivers a vasoactive medicine directly into erectile tissue. Alprostadil is a licensed injection option; other preparations used by specialist services vary. Injections can be effective when tablets fail because they act locally and do not depend on exactly the same nerve pathway.
Training is essential. The first dose is normally supervised so the response and technique can be assessed. Risks include penile pain, bruising or bleeding, scar tissue, an excessively prolonged erection and priapism. An erection lasting more than three to four hours needs emergency care.
Do not buy injection products from unregulated websites or use a dose supplied for another person.
Low-intensity shockwave therapy applies acoustic waves to penile tissue. The EAU reports a mild average improvement in erectile-function scores in men with vasculogenic ED and gives a weak recommendation for selected, well-informed patients, including some poor responders to PDE5 inhibitors.
It is not equivalent to a proven cure. Studies use different machines, energy settings and schedules, and benefit can decrease over time. Radial-wave treatments marketed as shockwave therapy are not the same as the focal low-intensity protocols used in much of the evidence. Ask the provider which device and protocol are being used, what improvement is realistic and what happens if treatment fails.
Platelet-rich plasma (PRP) and stem-cell injections are marketed for ED, but current evidence is insufficient for routine recommendation. The EAU notes conflicting and limited PRP data. These treatments should not be presented as established methods of restoring penile blood vessels or curing ED.
Supplements marketed for “male enhancement” may contain undeclared active medicines or interact with prescribed treatment. A product described as natural is not automatically safe.
A penile prosthesis places inflatable or malleable components inside the penis to create rigidity on demand. It may be offered when other treatments have failed or are unsuitable, or when a fully informed patient prefers an implant.
Implants generally provide high satisfaction in appropriately selected patients, but they require surgery. Infection, pain, erosion, mechanical failure and later revision are possible. Implantation permanently changes the natural erectile tissue, so counselling should cover expectations, device types, hand function, penile dimensions and what revision surgery may involve.
A structured review should check:
Treatment failure is not a reason to keep increasing doses without supervision. Men with severe vasculogenic, neurological or post-surgical ED may need a device, injection or implant even after tablets have been used correctly.
An implant can be discussed when tablets, devices or injections are ineffective, unsuitable or unacceptable, or when a man wants a definitive surgical option after full counselling. Referral to an experienced prosthetic urology service is appropriate.
